GHRP-6 Acetate

GHRP-6 Acetate (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is the foundational first-generation synthetic GHS-R1a agonist, developed by Cyril Bowers at Tulane University from structure-activity relationship studies of enkephalin analogues in the late 1970s and published in 1984. GHRP-6 was the key pharmacological tool that enabled identification and cloning of the GHS-R1a receptor by Howard et al. (Science, 1996) — making it historically significant as the compound that revealed the existence of the ghrelin receptor a decade before ghrelin itself was discovered. The published GHRP-6 research literature spanning more than 40 years provides an extensive pharmacological reference dataset for comparative research.

GHS-R1a was identified as an orphan receptor expressed in pituitary and hypothalamic tissue using GHRP-6 as the pharmacological probe for tissue distribution mapping. The receptor-cloning strategy used constitutively active mutant GPCRs alongside GHRP-6 binding data to narrow candidate receptor genes — establishing a template for orphan receptor deorphanisation. Ghrelin (Kojima et al., Nature, 1999) was subsequently identified as the natural GHS-R1a ligand through reverse pharmacology screening of tissue extracts for compounds that activated the cloned orphan receptor.

GHRP-6 activates GHS-R1a through Gq/11 coupling, triggering PLCbeta/IP3/calcium cascade and PKC activation. In pituitary somatotrophs, the calcium transient drives GH secretory granule exocytosis. Published dose-response data from multiple species establishes the EC50 for GH release at approximately 1-10 nM in most primary pituitary cell preparations. At saturating concentrations, GHRP-6 produces maximal GH release equivalent to or exceeding native GHRH under comparable conditions, making it useful as a positive control for maximal somatotroph activation.

The appetite-stimulating dimension of GHRP-6 pharmacology is the most pronounced among the GHRP series. GHRP-6 activation of GHS-R1a on arcuate nucleus NPY/AgRP orexigenic neurons drives NPY release (activating Y1/Y5 receptors in PVN to increase food intake) and AgRP release (antagonising anorexigenic MC4R). Published rodent food intake studies demonstrate that GHRP-6 increases meal frequency, meal size, and total caloric intake in satiated animals — effects mediated through the ghrelin/GHS-R1a appetite circuit. This orexigenic biology — absent from Ipamorelin at equivalent GH-releasing doses — represents a distinct pharmacological dimension for comparing across the GHRP series.

The His1-D-Trp2 motif at the GHRP-6 N-terminus is proposed to contribute to the compound's off-target receptor activities beyond GHS-R1a: ACTH stimulation, prolactin elevation, and appetite stimulation through NPY pathways have all been attributed to His1-D-Trp2-dependent receptor interactions that are absent in D-Ala1-D-beta-Nal2 GHRP-2 and Aib1-D-2-Nal3 Ipamorelin. This structure-selectivity relationship makes GHRP-6 a valuable tool for understanding which GHRP pharmacophore elements mediate which biological effects.

GHRP-6 contains two tryptophan residues (D-Trp2 and Trp4) making it susceptible to UV-induced oxidation and photodegradation. Store in amber containers and protect from light throughout experimental procedures. For research requiring precise GHS-R1a pharmacology without appetite or ACTH confounds, Ipamorelin is preferred; GHRP-6 is preferred when the complete historical GHRP pharmacology profile — including appetite circuit biology — is the research objective.